Form 4: Cytokinetics CEO Robert Blum Reports Stock Sale

Cytokinetics CEO Robert Blum sold 15,000 shares of common stock at $40.75 on March 31, 2025, according to a Form 4 filing.

Summary

• Robert I. Blum, President & CEO and Director of Cytokinetics Inc., reported a transaction involving the company's common stock on March 31, 2025.
• Blum sold 15,000 shares of common stock at a price of $40.75 per share.
• Following the transaction, Blum directly owns 427,629 shares of Cytokinetics Inc.
• Blum also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. Insider sales can sometimes be interpreted negatively, but without further context, it's difficult to assign a strong sentiment.

Industry Context

Form 4 filings are a routine part of the regulatory landscape, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future stock performance.

Stakeholder Impact

• Shareholders may react to the insider sale, potentially impacting the stock price.

Key Dates

Keywords

Form 4, insider trading, stock sale, Robert Blum, Cytokinetics, CYTK